Monlunabant
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
Inversago Pharma · Phase 2 · Completed · Enrollment 243
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Low dose | n/r | n/r | n/r | n/r |
| High dose | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
| Middle Dose | n/r | n/r | n/r | n/r |
Not shown
- Low dose: endpoint not reported
- High dose: endpoint not reported
- Placebo: endpoint not reported
- Middle Dose: endpoint not reported